Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?

doi:10.1007/s12094-011-0642-9

. 2011 Mar;13(3):209-10.

doi: 10.1007/s12094-011-0642-9.

Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?

Carmen Balañá, Olatz Etxaniz, Cristina Bugés, Alex Martínez

PMID: 21421467
DOI: 10.1007/s12094-011-0642-9

Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?

Carmen Balañá et al. Clin Transl Oncol. 2011 Mar.

. 2011 Mar;13(3):209-10.

doi: 10.1007/s12094-011-0642-9.

Authors

Carmen Balañá, Olatz Etxaniz, Cristina Bugés, Alex Martínez

PMID: 21421467
DOI: 10.1007/s12094-011-0642-9

No abstract available

PubMed Disclaimer

Cited by

High-dose salvage re-irradiation for recurrent/progressive adult diffuse glioma: healing or hurting?
Gupta T, Maitre M, Maitre P, Goda JS, Krishnatry R, Chatterjee A, Moiyadi A, Shetty P, Epari S, Sahay A, Patil V, Jalali R. Gupta T, et al. Clin Transl Oncol. 2021 Jul;23(7):1358-1367. doi: 10.1007/s12094-020-02526-0. Epub 2021 Feb 2. Clin Transl Oncol. 2021. PMID: 33528810
The efficacy of stereotactic radiotherapy followed by bevacizumab and temozolomide in the treatment of recurrent glioblastoma: a case report.
Zhong W, Mao J, Wu D, Peng J, Ye W. Zhong W, et al. Front Pharmacol. 2024 Sep 4;15:1401000. doi: 10.3389/fphar.2024.1401000. eCollection 2024. Front Pharmacol. 2024. PMID: 39295944 Free PMC article.
Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial.
Hovey EJ, Field KM, Rosenthal MA, Barnes EH, Cher L, Nowak AK, Wheeler H, Sawkins K, Livingstone A, Phal P, Goh C, Simes J; CABARET/COGNO investigators. Hovey EJ, et al. Neurooncol Pract. 2017 Sep;4(3):171-181. doi: 10.1093/nop/npw025. Epub 2017 May 25. Neurooncol Pract. 2017. PMID: 31386014 Free PMC article.
Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience.
Cerretti G, Bosio A, Librizzi G, Pintacuda G, Caccese M, Salvalaggio A, Zoccarato M, Parisi A, Padovan M, Maccari M, Cavallin F, Bellu L, Pasqualetti F, Ius T, Denaro L, Volpin F, Coppola M, Lonardi S, Lombardi G. Cerretti G, et al. J Neurooncol. 2025 Jun;173(2):449-456. doi: 10.1007/s11060-025-04992-4. Epub 2025 Mar 10. J Neurooncol. 2025. PMID: 40063186 Free PMC article.
Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects.
Pineda E, Domenech M, Hernández A, Comas S, Balaña C. Pineda E, et al. Onco Targets Ther. 2023 Jan 25;16:71-86. doi: 10.2147/OTT.S366371. eCollection 2023. Onco Targets Ther. 2023. PMID: 36721854 Free PMC article. Review.

See all "Cited by" articles

References

1. J Clin Oncol. 2009 Oct 1;27(28):4733-40 - PubMed
1. J Clin Oncol. 1999 Sep;17(9):2762-71 - PubMed
1. Neurol Clin. 2007 Nov;25(4):867-90, vii - PubMed
1. N Engl J Med. 2005 Mar 10;352(10):987-96 - PubMed
1. J Clin Oncol. 2009 Feb 10;27(5):740-5 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

[1] J Clin Oncol. 2009 Oct 1;27(28):4733-40 - PubMed

[2] J Clin Oncol. 2009 Oct 1;27(28):4733-40 - PubMed

[3] J Clin Oncol. 1999 Sep;17(9):2762-71 - PubMed

[4] J Clin Oncol. 1999 Sep;17(9):2762-71 - PubMed

[5] Neurol Clin. 2007 Nov;25(4):867-90, vii - PubMed

[6] Neurol Clin. 2007 Nov;25(4):867-90, vii - PubMed

[7] N Engl J Med. 2005 Mar 10;352(10):987-96 - PubMed

[8] N Engl J Med. 2005 Mar 10;352(10):987-96 - PubMed

[9] J Clin Oncol. 2009 Feb 10;27(5):740-5 - PubMed

[10] J Clin Oncol. 2009 Feb 10;27(5):740-5 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?

Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?

Authors

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Medical

Research Materials